Fundraising FoxVersant Ventures — 2020 Investments
5 investments dated 2020 · listed companies and verified rows first · show all
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in
Co-investorsAisling CapitalHBM PartnersNew Enterprise Associates (NEA)Amzak HealthAvoro Capital AdvisorsGV (Google Ventures)+4 more
T-knife Therapeutics is a biopharmaceutical company developing T cell therapies to treat cancer, with an initial focus on solid tumors.
BiotechHealthtechBerlin, DE
Elisa Kieback(Co-founder & Chief Technology Officer)inThomas Blankenstein(Scientific Founder)Thomas Soloway(Chief Executive Officer)Camille Landis(Chief Business Officer / Chief Financial Officer)inPeggy Sotiropoulou(Chief Scientific Officer)in
Co-investorsAndera PartnersEQT Life SciencesRA CapitalSixty Degree CapitalFidelity Investments
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Co-investorsLifeSci Venture PartnersSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossovervenBio Partners+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Jengu Therapeutics, Inc.VectivBio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.